Filing Flows › Sight Sciences (SGHT) › Surgical Glaucoma revenue
Sight Sciences (SGHT) Surgical Glaucoma revenue by quarter
Sight Sciences' Surgical Glaucoma revenue was $21.0M in Q3 2026 (third quarter 2026), +2% from Q2 2026. Over the last 7 quarters it ranged from $17.1M (Q1 2025) to $21.0M (Q3 2026).
| Quarter | Surgical Glaucoma revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $21.0M | +2% | +7% |
| Q2 2026 | $20.7M | +13% | +8% |
| Q1 2026 | $18.3M | -7% | +7% |
| Q4 2025 | $19.7M | -0.3% | — |
| Q3 2025 | $19.7M | +3% | — |
| Q2 2025 | $19.2M | +12% | — |
| Q1 2025 | $17.1M | — | — |
Q3 2026 at a glance
Sight Sciences, Q3 2026: revenue $24.9M (+25% year over year), operating margin -24.6%, net loss $6.8M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sight Sciences' Surgical Glaucoma revenue?
Sight Sciences' Surgical Glaucoma revenue was $21.0M in Q3 2026 (third quarter 2026), +2% from Q2 2026.
How has Sight Sciences' Surgical Glaucoma revenue changed?
Over the last 7 quarters it ranged from $17.1M (Q1 2025) to $21.0M (Q3 2026).